Pharmaceuticals China

China Duchenne Muscular Dystrophy Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Duchenne Muscular Dystrophy Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $322.4 Mn Placeholder estimate
Estimate 2025 $376.5 Mn 9.5% of the global market
Projected 2034 $1.52 Bn 304.6% Adds $1.15 Bn over 9 forecast years
CAGR 2025–2034 16.8% Faster than 78% of 183 Pharmaceuticals markets here
Key players 5 Companies profiled
  • China is 9.49% of the global market.
  • In APAC, the largest is China (this report) at $376.5 Mn.
  • Fastest growing: India at 17.7% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.15 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Duchenne Muscular Dystrophy Treatment Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $322.4 Mn — —
2025 (base) $376.5 Mn +$54.2 Mn —
2026 (forecast) $439.8 Mn +$63.3 Mn +16.8%
2027 (forecast) $513.7 Mn +$73.9 Mn +36.4%
2028 (forecast) $600.0 Mn +$86.3 Mn +59.3%
2029 (forecast) $700.8 Mn +$100.8 Mn +86.1%
2030 (forecast) $818.5 Mn +$117.7 Mn +117.4%
2031 (forecast) $956.0 Mn +$137.5 Mn +153.9%
2032 (forecast) $1.12 Bn +$160.6 Mn +196.6%
2033 (forecast) $1.30 Bn +$187.6 Mn +246.4%
2034 (forecast) $1.52 Bn +$219.1 Mn +304.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Duchenne Muscular Dystrophy Treatment Market Analysis at a glance
Market size, 2025$376.5 Mn placeholder estimate
Forecast, 2034$1.52 Bn placeholder estimate
Growth (CAGR), 2025–203416.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, age and end user (see all)
Key playersSarepta Therapeutics, PTC Therapeutics, Italfarmaco, Santhera Pharmaceuticals, NS Pharma (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials11 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Duchenne Muscular Dystrophy Treatment Market Analysis Executive Summary

Duchenne muscular dystrophy treatments slow muscle loss in boys with this genetic disease, using gene therapy, exon skipping and steroids.

Key segments of the duchenne Muscular Dystrophy Treatment market include treatment (Gene Therapy, Exon Skipping and Corticosteroids) and age (Children and Adolescents and Adults).

Bar chart: China Duchenne Muscular Dystrophy Treatment market size, 2024–2034, placeholder estimates. $322.4 Mn in 2024, $376.5 Mn in 2025 and $1.52 Bn in 2034, 16.8% CAGR.
China Duchenne Muscular Dystrophy Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Duchenne Muscular Dystrophy Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the duchenne Muscular Dystrophy Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the duchenne Muscular Dystrophy Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the duchenne Muscular Dystrophy Treatment market.

Competitive Landscape for Duchenne Muscular Dystrophy Treatment Market in China

The duchenne Muscular Dystrophy Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Duchenne Muscular Dystrophy Treatment Market in China

Duchenne Muscular Dystrophy Treatment in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 11 studies on Duchenne Muscular Dystrophy Treatment that are recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for duchenne Muscular Dystrophy Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Duchenne Muscular Dystrophy Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Duchenne Muscular Dystrophy Treatment in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 7th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Duchenne Muscular Dystrophy Treatment market in China?
Placeholder estimate: about $376.5 Mn in 2025, rising to about $1.52 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Duchenne Muscular Dystrophy Treatment market in China growing?
Placeholder estimate: about 16.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Duchenne Muscular Dystrophy Treatment market report cover?
The report splits the market by treatment (Gene Therapy, Exon Skipping, Corticosteroids, Others), age (Children, Adolescents and Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Duchenne Muscular Dystrophy Treatment market?
Key players include Sarepta Therapeutics, PTC Therapeutics, Italfarmaco, Santhera Pharmaceuticals and NS Pharma.
What is driving the Duchenne Muscular Dystrophy Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the duchenne Muscular Dystrophy Treatment market. More countries now have national rare disease plans.
Who regulates Duchenne Muscular Dystrophy Treatment in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Duchenne Muscular Dystrophy Treatment are running in China?
11 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Duchenne Muscular Dystrophy Treatment?
PubMed lists 2,436 papers on Duchenne Muscular Dystrophy Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on rare diseases and brain and nerves

See the topic